Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuvalent, Inc. (NUVL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nuvalent is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, and its filings offer detailed information on clinical progress, financing activities, and key business agreements related to its targeted oncology pipeline.
Recent Form 8-K filings describe pivotal and preliminary data for neladalkib in ALK-positive NSCLC from the ALKOVE-1 Phase 1/2 trial, pivotal data for zidesamtinib in ROS1-positive NSCLC from the ARROS-1 Phase 1/2 trial, and the initiation of the ALKAZAR Phase 3 trial in TKI-naïve ALK-positive NSCLC. Other 8-Ks outline the completion and FDA acceptance of a New Drug Application for zidesamtinib in TKI pre-treated ROS1-positive NSCLC, plans for an NDA submission for neladalkib, and the assignment of a PDUFA target action date for zidesamtinib.
Filings also document Nuvalent’s capital markets activity, including an underwriting agreement for a public offering of Class A common stock under an automatically effective shelf registration statement on Form S-3, and the company’s estimate that proceeds from the offering, together with existing cash, cash equivalents, and marketable securities, would fund operations into 2029. Additional disclosures cover a preexisting royalty interest on future net sales of neladalkib and zidesamtinib, as well as periodic 8-Ks furnishing quarterly financial results press releases.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight the main points of each document, helping readers quickly understand clinical data updates, NDA milestones, financing terms, and other material events. Users can review 10-K and 10-Q reports, 8-K current reports, registration statements, and exhibits, and use the AI-generated insights to navigate lengthy technical and legal language more efficiently while researching NUVL.
The Vanguard Group filed an amendment to Schedule 13G reporting zero beneficial ownership of Nuvalent Inc. common stock. The filing states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The Schedule 13G/A shows 0 shares and 0% ownership and is signed by Ashley Grim on 03/27/2026.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported an exercise-and-sale set of transactions in company stock. On March 24, 2026, she exercised stock options for 11,430 shares of Class A Common Stock at $1.08 per share and sold 11,430 shares that day in open-market trades at weighted-average prices in the mid-$90s. She then sold an additional 13,700 shares on March 25, 2026 at a weighted-average price of $100.16 per share in open-market transactions. All sales were executed under a Rule 10b5-1 trading plan adopted on December 23, 2025. After these transactions, she directly holds 85,533 shares of Nuvalent Class A Common Stock.
NUVL filed a Form 144 notice reporting proposed sales of Class A Common shares. The notice lists multiple lots and dates with specific quantities, including 30,019, 15,701, 4,728 and 8,972 shares tied to option exercises and cash transactions.
The filing identifies transactions dated 03/24/2026 and 12/17/2024 and names J.P. Morgan Securities LLC as an intermediary. The submission is a resale notice of insider-held securities under Form 144.
Nuvalent, Inc. officer Benjamin Lane filed an initial ownership report, listing his equity stake in the company. He directly holds 40,868 shares of Class A Common Stock, along with multiple stock options and restricted stock units that may convert into additional shares over time.
The filing shows stock options over 731, 8,333, 17,848, 15,052, 12,025 and 8,000 shares of Class A Common Stock, with exercise prices from $14.40 to $106.82 and expirations between 2032 and 2036. Footnotes also describe RSUs covering 6,733, 5,200 and 8,000 shares that vest in installments, subject to continued service. The Form 3 reflects holdings rather than new buy or sell transactions.
Nuvalent, Inc.’s Chief Scientific Officer Henry E. Pelish exercised stock options and sold shares of Class A Common Stock in mid-March 2026. He exercised options covering 17,320 shares at strike prices between $18.93 and $72.35, converting them into common shares.
On March 12–13, 2026, he then executed open-market sales totaling 35,104 shares at weighted average prices around the high‑$90s, in multiple trades across price ranges from $97.08 to $100.14. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. After these transactions, Pelish directly holds 65,604 shares of Nuvalent Class A Common Stock.
NUVL reported proposed and recent sales of common stock by an affiliate. The filing lists proposed sales tied to option exercises and restricted stock units, and discloses two completed sales by Henry E. Pelish on 01/05/2026 (2,496 shares for $242,905.02) and 01/06/2026 (2,664 shares for $258,847.87). The schedule also shows prior and planned issuances from option exercises and RSU vesting with quantities listed by grant date.
Nuvalent, Inc. President and CEO James Richard Porter exercised stock options for 30,000 shares of Class A common stock at an exercise price of $27.85 per share. These options were part of a grant vesting monthly over four years from January 6, 2023.
On the same date, he sold 30,000 shares of Class A common stock in open-market transactions at weighted average prices of about $98.59, $99.29 and $100.19, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2025. Following these transactions, he directly holds 324,879 shares of Nuvalent Class A common stock.
Nuvalent, Inc.’s Chief Development Officer Darlene Noci reported option exercises and share sales. On February 26, 2026, she exercised stock options for 5,500 shares of Class A common stock and acquired those shares via derivative conversion.
On the same date, she sold a total of 5,500 Class A common shares in open-market transactions at weighted average prices between $102.04 and $104.41 per share, under a Rule 10b5-1 trading plan adopted on November 18, 2024. After these transactions, she held 58,117 Class A common shares directly.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller exercised stock options for 5,500 shares of Class A common stock on February 26, 2026, converting a derivative security into common stock at an exercise price of approximately $6.89 per share. On the same date, she sold a total of 5,500 shares of Class A common stock in open-market transactions at weighted average prices ranging from $101.96 to $103.95, pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024. Following these transactions, she directly held 59,634 shares of Class A common stock and 89,108 derivative securities.